CSIMarket
 


Neximmune Inc   (NEXI)
Other Ticker:  
 

Neximmune Inc 's Tangible Leverage Ratio

NEXI's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -2.53%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 0.76 reached a new all-time high.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 262 other companies have achieved lower Tangible Leverage Ratio than Neximmune Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 872 to 1364 .

Explain Tangible Leverage Ratio?
What is NEXI Market Share?
What are NEXI´s Total Liabilities?


NEXI Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -82.7 % -69.56 % -66.51 % -61.44 % -50.86 %
Y / Y Total Liabilities Change -36.66 % -34.05 % -10.53 % 47.97 % 33.99 %
Tangible Leverage Ratio MRQ 0.76 0.38 0.3 0.33 0.21
NEXI's Total Ranking # 1364 # 872 # 749 # 905 # 553
Seq. Tangible Equity Change -51.45 % -27.89 % -27 % -32.31 % -14.57 %
Seq. Total Liabilities Change -2.53 % -8.68 % -34.14 % 8.04 % 1.48 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 263
Healthcare Sector # 519
Overall Market # 1364


Tangible Leverage Ratio Statistics
High Average Low
0.76 0.23 0.05
(Sep 30 2023)   (Jun 30 2021)




Financial Statements
Neximmune Inc 's Tangible Equity $ 8 Millions Visit NEXI's Balance sheet
Neximmune Inc 's Total Liabilities $ 6 Millions Visit NEXI's Balance sheet
Source of NEXI's Sales Visit NEXI's Sales by Geography


Cumulative Neximmune Inc 's Tangible Leverage Ratio

NEXI's Tangible Leverage Ratio for the trailling 12 Months

NEXI Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -82.7 % -69.56 % -66.51 % -61.44 % -50.86 %
Y / Y Total Liabilities TTM Growth -36.66 % -34.05 % -10.53 % 47.97 % 33.99 %
Tangible Leverage Ratio TTM 0.38 0.28 0.24 0.19 0.14
Total Ranking TTM # 5 # 3 # 674 # 2 # 338
Seq. Tangible Equity TTM Growth -51.45 % -27.89 % -27 % -32.31 % -14.57 %
Seq. Total Liabilities TTM Growth -2.53 % -8.68 % -34.14 % 8.04 % 1.48 %


  News about Neximmune Inc Tangible Leverage Ratio

NexImmune's Financial Dilemma: High Leverage Ratio Despite Successful Offerings


NexImmune's Tangible Leverage Ratio Reaches New All-Time High Despite Borrowings
NexImmune recently announced the closing of a $3.67 million registered direct offering priced at-the-market under Nasdaq rules. This comes at a time when the company's Tangible Leverage Ratio has deteriorated to 0.76 in the third quarter of 2023, reaching a new all-time high.
In comparison to 262 other companies within the industry, NexImmune's Tangible Leverage Ratio ranks higher, indicating a concerning trend. The company's position has worsened from 0.38 in the second quarter of 2023 to 1364 in the latest report. However, when considering the trailing twelve months, NexImmune's Tangible Leverage Ratio has actually improved to 0.38 due to repayments of liabilities.


On the trailing twelve months basis Despite of the repayements of liabilities of -2.53% in the trailing twelve months ending in III Quarter 2023, Tangible Leverage Ratio improved to 0.38, above Neximmune Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 262, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Neximmune Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 3 to 5.

Explain Tangible Leverage Ratio?
What is NEXI Market Share?
What are NEXI´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 263
Healthcare Sector # 519
Within the Market # 5


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.76 0.23 0.05
(Sep 30 2023)   (Jun 30 2021)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
G1 Therapeutics Inc   2.09 $ 90.075  Millions$ 43.022  Millions
China Pharma Holdings Inc   2.07 $ 9.241  Millions$ 4.469  Millions
Milestone Pharmaceuticals inc   2.06 $ 58.612  Millions$ 28.504  Millions
Cerevel Therapeutics Holdings Inc   2.01 $ 549.000  Millions$ 272.962  Millions
Abeona Therapeutics Inc   2.00 $ 44.049  Millions$ 22.038  Millions
Cyclacel Pharmaceuticals Inc   1.91 $ 8.200  Millions$ 4.297  Millions
Cv Sciences Inc   1.88 $ 6.061  Millions$ 3.228  Millions
Syros Pharmaceuticals Inc   1.87 $ 67.800  Millions$ 36.302  Millions
Catalyst Biosciences Inc   1.83 $ 6.447  Millions$ 3.517  Millions
Clene Inc   1.82 $ 39.027  Millions$ 21.406  Millions
Enveric Biosciences Inc   1.78 $ 3.883  Millions$ 2.183  Millions
Nektar Therapeutics  1.77 $ 282.876  Millions$ 159.368  Millions
First Wave Biopharma Inc   1.66 $ 2.648  Millions$ 1.595  Millions
Promis Neurosciences inc   1.65 $ 11.121  Millions$ 6.737  Millions
Soligenix inc   1.65 $ 6.963  Millions$ 4.221  Millions
Axsome Therapeutics Inc   1.64 $ 331.349  Millions$ 202.573  Millions
Liquidia Corporation  1.57 $ 63.635  Millions$ 40.612  Millions
Maia Biotechnology Inc   1.55 $ 4.253  Millions$ 2.748  Millions
Rani Therapeutics Holdings Inc   1.52 $ 52.883  Millions$ 34.819  Millions
Avid Bioservices Inc   1.48 $ 270.967  Millions$ 183.675  Millions
Lexicon Pharmaceuticals Inc   1.44 $ 136.969  Millions$ 94.967  Millions
Vaxxinity Inc   1.42 $ 33.774  Millions$ 23.705  Millions
Sonoma Pharmaceuticals Inc   1.40 $ 7.960  Millions$ 5.675  Millions
Supernus Pharmaceuticals inc   1.37 $ 210.496  Millions$ 154.025  Millions
Pds Biotechnology Corp  1.34 $ 32.704  Millions$ 24.484  Millions
Elicio Therapeutics Inc   1.33 $ 17.701  Millions$ 13.286  Millions
Atreca inc   1.33 $ 14.302  Millions$ 10.759  Millions
Arvinas Inc   1.31 $ 601.100  Millions$ 457.200  Millions
Carisma Therapeutics Inc   1.31 $ 60.486  Millions$ 46.298  Millions
Transcode Therapeutics Inc   1.30 $ 5.788  Millions$ 4.440  Millions

Date modified: 2023-11-21T19:09:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com